Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration

Table 1 Clinical information description of hepatocellular carcinoma patients in The Cancer Genome Atlas

Description	Samples, n = 371	Percentage
Sex
Male	249	67.11
Female	121	32.61
Others	1	0.27
Race
White	184	49.60
Asian	158	42.59
Black or African American	16	4.31
Others	13	3.50
Vital status
Alive	240	64.69
Dead	130	35.14
Others	1	0.27
Age at diagnosis
≥ 60-years-old	197	53.10
< 60-years-old	169	45.55
Others	5	1.35
AJCC pathologic T
T1	180	48.52
T2	92	24.80
T2a	1	0.27
T2b	1	0.27
T3	45	12.13
T3a	29	7.82
T3b	6	1.62
T4	13	3.50
TX	1	0.27
Others	1	0.27
AJCC system for tumor staging
N0	239	64.42
N1	4	1.08
Nx	91	24.53
Others	2	0.54
AJCC system for metastasis staging
M0	265	71.43
M1	4	1.08
Mx	101	27.22
Others	1	0.27
AJCC system for stage
Stage I	170	45.82
Stage II	86	23.18
Stage III	3	0.81
Stage IIIA	65	17.52
Stage IIIB	8	2.16
Stage IIIC	9	2.43
Stage IV	2	0.54
Stage IVA	1	0.27
Stage IVB	2	0.54
Others	25	6.74
Prior malignancy
Yes	35	9.43
No	335	90.30
Others	1	0.27
Treatment or therapy
Yes	38	10.24
No	309	83.28
Others	24	6.47

AJCC: American Joint Committee on Cancer.